IDH2 and central nervous system cancer: The first demonstrations of RCG in cancer cells [22, 23, 41] are consistent with the recent findings that mutant IDH2 in gliomas and AML also produce d-2-hydroxyglutarate from 2OG by “alternate” reduction.